Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Esophageal Neoplasms 6Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Melanoma 4Advanced NSCLC 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Neoplasms 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Leukemia, Myeloid, Acute 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

Cyclophosphamide 21fludarabine 14Rituximab 11Immunotherapy, Adoptive 9Specimen Handling 8Vincristine 7Prednisone 7Magnetic Resonance Spectroscopy 7Doxorubicin 7Etoposide 6Biopsy 6glofitamab 5zanubrutinib 4polatuzumab vedotin 4obinutuzumab 4Lenalidomide 4Bendamustine Hydrochloride 4relmacabtagene autoleucel 3loncastuximab tesirine 3fludarabine phosphate 3axicabtagene ciloleucel 3Leukapheresis 3Ifosfamide 3Carboplatin 3tafasitamab 2etoposide phosphate 2X-Rays 2Nivolumab 2Injections 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, B-Cell × Immune Checkpoint Inhibitors × Clear all
NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Sun Yat-sen University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡